mRNA Size Analysis Service
Overview
In the rapidly evolving landscape of therapeutic nucleic acids, the mRNA size analysis service stands as a cornerstone of structural characterization. As a critical component of the mRNA-based vaccine development platform at CD BioGlyco, this service ensures the precise determination of transcript length, integrity, and purity. Since the size of messenger RNA (mRNA) directly correlates with its ability to encode complete proteins, any deviation compromises the efficacy and safety of the final therapeutic product. Our specialized analysis provides the high-resolution data necessary to confirm that the drug substance meets the stringent specifications.
Key Technologies
- Capillary Gel Electrophoresis (CGE) with Laser-Induced Fluorescence (LIF)
By utilizing a gel matrix within a narrow capillary, we achieve high-resolution separation based on molecular size. The addition of LIF detection allows for the quantification of even trace amounts of degraded fragments or impurities, providing a detailed "fingerprint" of the mRNA population. - Size-Exclusion Chromatography coupled with Multi-Angle Light Scattering (SEC-MALS)
SEC-MALS provides an absolute measurement of molecular weight (Mw) and the polydispersity index (PDI) without relying on external standards. This technology is particularly effective for detecting higher-order structures and aggregates.
Precision Size Analysis for Potent mRNA Therapeutics
At CD BioGlyco, our service scope is meticulously designed to support the entire lifecycle of mRNA development, from initial in vitro transcription (IVT) optimization to final batch release. Under the umbrella of mRNA structural characterization, we offer a comprehensive analysis that goes beyond simple length measurement. Our capabilities include:
- Full-Length mRNA Verification: Determining the exact distribution of transcript lengths to ensure the presence of the complete open reading frame (ORF).
- Impurity Profiling: Identifying and quantifying sub-populations, such as aborted transcripts, double-stranded RNA (dsRNA) byproducts, and degraded RNA species.
- Poly(A) Tail Impact Assessment: Analyzing how variations in the polyadenosine tail influence the overall apparent size and stability of the mRNA.
- Aggregation Analysis: Utilizing biophysical methods to detect non-covalent and covalent aggregates that may impact the immunogenicity of mRNA-based vaccines.
By integrating these methods into the therapeutic nucleic acid development platform, we help researchers navigate the complexities of mRNA structural variations, ensuring that every batch is characterized with the utmost precision.
Workflow
Sample Reception and Pre-analytical Assessment
Upon receiving the mRNA samples, our team performs an initial quality check to assess concentration and basic purity. This stage ensures that the sample matrix is compatible with our high-resolution instruments.
Tailored Sample Preparation
Samples are prepared using RNA-specific buffers and denaturing agents. For CGE, samples are often heat-denatured to resolve secondary structures, ensuring that separation is strictly dependent on the primary nucleotide length.
High-Resolution Separation
In CGE, molecules migrate through a polymer network under a high-voltage electric field. In the SEC, the mRNA is separated through wide-pore columns specifically selected for large biomolecules.
Real-Time Detection and Signal Acquisition
LIF provides high-sensitivity fluorescence signals for CGE, while the MALS detector captures light scattering at multiple angles to calculate the absolute mass of the species in real-time.
Data Processing and Sizing Calculation
Our bioinformaticians use advanced software to convert raw signals into sizing data. This involves comparing migration times against internal standards for CGE.
Comprehensive Reporting and Consulting
We provide electropherograms, molar mass distributions, and a summary of the percentage of full-length mRNA. Our experts are available to discuss the results and suggest optimizations for your development process.
Publication Data
DoI: 10.1101/2022.02.14.480356
Journal: bioRxiv
Published: 2022
Results: This study develops an automated, high-throughput workflow for rapid characterization and sequence mapping of large RNAs and mRNA therapeutics. The workflow combines partial RNase T1 digestion with high-resolution liquid chromatography-tandem mass spectrometry (LC-MS/MS) and automated oligoribonucleotide identification via MS/MS spectra. Controlled partial digestion generates longer, uniquely mappable fragments, overcoming limitations of complete digestion. The method achieves >80% sequence coverage (up to 95.9% for eGFP mRNA without poly-A tail) in a single 90-minute analysis, including chemically modified mRNAs. It demonstrates specificity, reproducibility, and the ability to detect RNA impurities. This tool supports identity testing, sequence validation, and impurity analysis, addressing critical needs for mRNA therapeutic quality control.
Fig.1 mRNA sequence mapping. (Vanhinsbergh, et al., 2022)
Applications
Vaccine Development and Quality Control
Size analysis is essential for verifying that mRNA vaccines contain the full-length sequence required to produce the target antigen. Our services ensure batch-to-batch consistency during the manufacturing process.
Gene Therapy Research
We provide the high-resolution data needed to confirm that the therapeutic mRNA reaches the target length without significant fragmentation.
IVT Process Optimization
Researchers use our sizing data to evaluate the impact of different T7 RNA polymerase variants or nucleotide concentrations on transcription efficiency, minimizing the production of shortened or truncated mRNA species.
RNA Interference and Small RNA Characterization
While focused on large mRNA, our platforms are versatile enough to characterize the size and purity of smaller therapeutic RNAs, ensuring that the processing of precursor molecules is accurate and efficient.
Advantages
Low Sample Requirements
Our microfluidic and capillary-based systems are designed to operate with minimal sample volumes, preserving your precious therapeutic mRNA for further downstream applications and functional assays.
Scalable High-Throughput Processing
CD BioGlyco features automated systems capable of handling large batches of samples simultaneously, significantly reducing turnaround times for projects involving extensive library screening or large-scale manufacturing support.
Rigorous Quality Management
All analyses are conducted in a controlled environment following stringent protocols, ensuring that the data generated meets the high standards required for research.
Expert Interpretive Support Services
Beyond providing raw data, our PhD-level scientists offer in-depth interpretation of sizing results, helping you understand the structural implications of the data for your specific mRNA vaccine candidate.
Frequently Asked Questions
Customer Review
The resolution provided by CD BioGlyco's sizing service was instrumental in identifying a persistent truncation issue in our IVT process. Their team helped us interpret the electropherograms, leading to a 30% increase in our full-length mRNA yield.
— Dr. L.S., Senior Scientist
We were particularly impressed with the SEC-MALS data. The report was detailed and professionally presented.
— A.G., Director of Analytical Development
The ability to characterize very long saRNA transcripts with such precision is a testament to their advanced platform. We will certainly continue our partnership for future projects.
— A.T., Principal Investigator
Associated Services
CD BioGlyco provides a world-class mRNA size analysis service that serves as a vital pillar for mRNA structural characterization. By combining cutting-edge CGE and SEC-MALS technologies with deep scientific expertise, we ensure that your mRNA therapeutics are sized with precision, purity, and absolute accuracy. Please feel free to contact us to discuss your project or request a detailed quotation.
Reference
- Vanhinsbergh, C.J.; et al. Characterisation and sequence mapping of large RNA and mRNA therapeutics using mass spectrometry. bioRxiv. 2022. (Open Access)
- Glyco™ Synthesis Platform
- Custom Glycoprotein Synthesis
- Custom Glycoside Synthesis
- Custom Glycosyl Donor Synthesis
- Custom Thioglycoside Synthesis
- Custom Phosphatidylinositol Synthesis
- Custom Cyclodextrin Synthesis
- Custom Rhamnolipid Synthesis
- Custom Sphingolipid Synthesis
- Custom Building Block Synthesis
- Carbohydrate Manufacturing
- Synthesis Process Development and Optimization
- Custom Carbohydrate Synthesis
- Custom Glycolipid Synthesis
- Custom Glycopeptide Synthesis
- Custom Glycoconjugate Synthesis
- Custom Sugar-Nucleotide Synthesis
- Nucleoside & Nucleotide Synthesis Service
- Custom Oligonucleotide Synthesis Service
- Polynucleotide Synthesis Service
- Nucleoside & Nucleotide Modification Service
- Oligonucleotide Modification Service
- Nucleoside-based Production Service
- Nucleotide-based Production Service
- OPME-based NDP-sugar Synthesis Service
- OPME-based NMP-sugar Synthesis Service
- Glycomics Platform
- Glycoproteomics Platform
- N-Glycoproteomics of PDX Models
- Nanotechnologies for the Detection of Glycopeptides
- Glycoprotein Enrichment
- Glycoprotein Quantification
- Glyco-biomarker Detection Service
- Glyco-biomarker AFP Detection Service
- Glyco-biomarker CA19-9 Detection Service
- Glyco-biomarker CA125 Detection Service
- Glyco-biomarker CA15–3 Detection Service
- Glyco-biomarker CEA Detection Service
- Glyco-biomarker PSA Detection Service
- Glyco-biomarker Immunoglobulin G (IgG) Detection Service
- Glyco-biomarker Haptoglobin (Hp) Detection Service
- Glyco-biomarker α1-Antitrypsin (A1AT) Detection Service
- Glyco-biomarker α1-Acid Glycoprotein (AGP) Detection Service
- Glyco-biomarker Ceruloplasmin (CP) Detection Service
- Glyco-biomarker Fetuin A Detection Service
- Site Occupation
- Glycoprotein Structure Analysis
- Glycosylation Site-specific Antibody-Drug Conjugate (ADC) Development Platform
- Carbohydrate-based Glycomedicine Development Platform
- By Sources of Carbohydrate
- By Types of Carbohydrate
- Monosaccharides-based Glycomedicine Development
- Disaccharides-based Glycomedicine Development
- Trisaccharides-based Glycomedicine Development
- Oligosaccharides-based Glycomedicine Development
- Polysaccharides-based Glycomedicine Development
- Glycosides-based Glycomedicine Development
- Glycopeptide-based Glycomedicine Development
- Glycomimetic-based Glycomedicine Development
- By Applications of-based Glycomedicines
- Carbohydrate-based Anticoagulant Glycomedicine Development
- Carbohydrate-based Cardiovascular Glycomedicine Development
- Carbohydrate-based Antitumor Glycomedicine Development
- Carbohydrate-based Antidiabetic Glycomedicine Development
- Carbohydrate-based Antibacterial Glycomedicine Development
- Carbohydrate-based Antiviral Glycomedicines Development
- Carbohydrate-based Antiparasiti Glycomedicine Development
- By Discovery Strategies
- Glycoengineering-based Glycomedicine Development
- Production of Food Ingredients
- Multi-omics Platform for Cancer Glucose Metabolism (MOPCGM)
- Cancer Cell Glycolytic Analysis
- Cancer Cell TCA Cycle Analysis
- Cancer Cell PPP Analysis
- Gene-level Regulation Analysis of Cancer Glucose Metabolism
- Interplay Between Glucose Metabolism Reprogramming and Tumorigenesis & Progression
- Interplay Between Glucose Metabolism Reprogramming and Proliferative Signaling
- Interplay Between Glucose Metabolism Reprogramming and Growth Suppressor
- Interplay Between Glucose Metabolism Reprogramming and Cancer Cell Death
- Interplay Between Glucose Metabolism Reprogramming and Replicative Immortality
- Interplay Between Glucose Metabolism Reprogramming and Angiogenesis
- Interplay Between Glucose Metabolism Reprogramming and Invasion & Metastasis
- Interplay Between Glucose Metabolism Reprogramming and Immune Escape
- Interplay Between Glucose Metabolism Reprogramming and Genomic Instability
- Interplay Between Glucose Metabolism Reprogramming and Tumor-associated Inflammation
- Glucose Metabolism-Microenvironment Crosstalk Analysis in Cancer
- Cancer Glucose Metabolism In Vivo Analysis
- Applications of Studing Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism Small Molecule Inhibitor
- Discovery of Cancer Glucose Metabolism Therapeutic Monoclonal Antibodies
- Development of Gene Therapy Targeting Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism CAR-T Therapy Targeting
- Discovery of Cancer Glucose Metabolism Combination Therapy Strategy
- Discovery of Cancer Glucose Metabolism Precision Therapeutic Strategies
- Glycoengineering Platform
- Therapeutic Nucleic Acid Development Platform
- Therapeutic Oligonucleotide Synthesis Service
- siRNA Synthesis
- miRNA Synthesis
- ASO Synthesis
- Aptamer Synthesis
- PMO Synthesis
- sgRNA Synthesis
- Circular RNA Synthesis
- PNA Synthesis
- Lipid-based GalNac-RNA Delivery Service
- CpG Oligonucleotide Synthesis
- Click-based GalNac-RNA Delivery Service
- AntimiR Synthesis
- GalNAc-siRNA Delivery Service
- tRNA Synthesis
- GalNAc-ASO Delivery Service
- saRNA Synthesis
- Reporter Gene mRNA Synthesis
- Gene Editing mRNA Synthesis
- Gene Replacement mRNA Synthesis
- Cre Recombinase mRNA Synthesis
- hEPO mRNA Synthesis
- OVA mRNA Synthesis
- Therapeutic Oligonucleotide Modification Service
- Therapeutic Oligonucleotide Delivery Development Service
- Targeted Ligand and Linker Synthesis
- Monoantennary GalNac-RNA Delivery
- Biantennary GalNac-RNA Delivery
- Triantennary GalNac-RNA Delivery
- Tetra-antennary GalNac-RNA Delivery
- Solution Phase-based GalNac-RNA Delivery
- Solid Phase-based GalNac-RNA Delivery
- mRNA Poly(A) Tail Length Analysis
- GalNAc-siRNA Delivery
- GalNAc-ASO Delivery
- GalNAc-miRNA Delivery
- GalNAc-Aptamer Delivery
- GalNAc-AntimiR Delivery
- GalNAc-mRNA Delivery
- GalNAc-PNA Delivery
- Peptide-Therapeutic Oligonucleotide Delivery
- LNP-Therapeutic Oligonucleotide Delivery
- PEG-Therapeutic Oligonucleotide Delivery
- Biological Evaluation Service for Therapeutic Oligonucleotide
- mRNA-based Vaccine Development Service
- mRNA Sequence Design&Optimization Service
- mRNA Integrity Analysis ServicemRNA Integrity Analysis Service
- mRNA Biodistribution Analysis Service
- DNA Template Preparation Service
- mRNA Purity Analysis Service
- T Cell Cytokine Secretion Analysis Service
- mRNA Modification Service
- mRNA Length Analysis Service
- mRNA Purification Service
- Neutralizing Antibody Assay Service
- mRNA-LNP Formulation and Encapsulation Service
- mRNA Structural Characterization
- mRNA Structural Characterization Service
- mRNA Bioanalysis Service
- mRNA Residual DNA Template Analysis Service
- mRNA Residual Double-Stranded RNA (dsRNA) Analysis Service
- mRNA Size Analysis Service
- mRNA Polydispersity Analysis Service
- mRNA Zeta Potential Analysis Service
- mRNA Lipid Composition Analysis Service
- Oligonucleotide Drug Process and Formulation Development Service
- RNA Drug Process and Formulation Development
- Therapeutic Oligonucleotide Synthesis Service
- Glycobiology Microarray Platform
- Glyco™ Vaccine Development Platform
- Carbohydrate-based Vaccine Development
- Polysaccharide Vaccine Development
- Tumor-Associated Carbohydrate Vaccine Development
- Glycoconjugate Vaccine Development
- Natural Carbohydrate-based Vaccine Development
- Semi-synthetic Carbohydrate-based Vaccine Development
- Fully Synthetic Carbohydrate-based Vaccine Development
- Carbohydrate-based Antibacterial Vaccine Development
- Carbohydrate-based Antifungal Vaccine Development
- Carbohydrate-based Antiparasitic Vaccine Development
- Carbohydrate-based Antiviral Vaccine Development
- Carbohydrate-based Anticancer Vaccine Development
- Carbohydrate-based Antihelmintic Vaccine Development
- Monovalent Carbohydrate-based Vaccine Development
- Polyvalent Carbohydrate-based Vaccine Development
- Carrier Protein Design Service
- Carbohydrate Conjugation Service for Vaccine Development
- Carbohydrate-based Adjuvant Development
- Lipopolysaccharide-based Adjuvant Development
- Bacterial Outer Membrane Vesicles (OMVs)-based Adjuvant Development
- Trehalose Glycolipid-based Adjuvant Development
- Galactosylceramide-based Adjuvant Development
- Peptidoglycan-based Adjuvant Development
- Chitin/Chitosan-based Adjuvant Development
- Inulin-based Adjuvant Development
- Mannans-based Adjuvant Development
- Alginate-based Adjuvant Development
- Saponin-based Adjuvant Development
- α-Glucan-based Adjuvant Development
- Lentinan-based Adjuvant Development
- β-Glucans-based Adjuvant Development
- Deltin-based Adjuvant Development
- Muramyldipeptide-based Adjuvant Development
- Cord Factor-based Adjuvant Development
- Zwitterionic Polysaccharide-based Adjuvant Development
- Novel Plant Polysaccharides-based Adjuvant Development
- Glycoprotein-based Vaccine Development
- Glycopeptide-based Vaccine Development
- Carbohydrate-based Vaccine Development
- Glycogenomics Platform
- Glycogene Editing Service
- Glycogene Delivery Service
- Glycogene Expression Profiling
- Cancer Glycogene Discovery Service
- Glycogene Discovery Service in Cervical Cancer
- Glycogene Discovery Service in Leukemia
- Glycogene Discovery Service in Bladder Cancer
- Glycogene Discovery Service in Colorectal Adenocarcinoma
- Glycogene Discovery Service in Liver Cancer
- Glycogene Discovery Service in Lymphoma
- Glycogene Discovery Service in Breast Cancer
- Glycogene Discovery Service in Prostate Cancer
- Glycogene Discovery Service in Pancreatic Cancer
- Glycogene Discovery Service in Lung Cancer
- Glycogene Discovery Service in Thyroid Cancer
- Glycogene Discovery Service in Ovarian Cancer
- Glycan Display Platform
- Traditional Glycan Display Array
- Natural Oligosaccharide Library Construction Service
- Chemical Synthesis-based Oligosaccharide Library Construction Service
- Enzymatic Synthesis-based Oligosaccharide Library Construction Service
- Modular Synthesis-based Oligosaccharide Library Construction Service
- Oligosaccharide Library Immobilization Service
- Cell-based Glycan Display Array
- Neoglycolipid (NGL) Display Array
- Liquid Glycan Display Array (LiGA)
- Glycophage Display
- N-linked Glycoprotein-based Glycophage Display System Construction Service
- O-linked Glycoprotein-based Glycophage Display System Construction Service
- Glycophage Display-based Glycosylase Genetic Analysis Service
- Glycophag Display-based Glycoarray Service
- Glycophage Display-based Antibody Development Service
- Glycophage Display-based Epitope Mapping Service
- Glycophage Display-based Biomarker Development Service
- De Novo Glycan Display
- Cell-Surface Glycan Editing
- Examining the Effects of Altering Blood Group Antigens on Erythrocyte Cell Surfaces
- Preventing Cellular Rejection During Transplantation
- Modulating Chemical Composition and Physical Parameters of Glycocalyx
- Tailoring Cell Membranes with Biologically Active Glycans
- Targeting Glycosaminoglycan-mediated Growth Factor Signaling to Influence Stem Cell Specification
- Long-term De Novo Glycan Display for Directing Stem Cell Fate
- Traditional Glycan Display Array
- GlycoNano™ Platform
- Glyconanoparticle Development Service
- Techniques for Glyconanoparticle Development
- Carbohydrate-based Nanoparticle Production
- Gold Glyconanoparticle Production
- Silver Glyconanoparticle
- Magnetic Glyconanoparticle
- Quantum Dot (QD) Glyconanoparticle
- Glyconanoparticle Characterization
- PEG Glyconanoparticle
- Carbon-based Glyconanoparticle
- Fluorescent Glyconanoparticle
- Silica Glyconanoparticle
- Liposome Glyconanoparticle
- Glycol Nanohydrogel Development
- Glycol Nanorod
- Glycol Nanotube
- Glycol Nanocrystal/Nanosheet/Nanosphere/Nanofiber
- Glyconanoparticle Preclinical Study
- Glyconanoparticle Formulation
- Glyconanotechnology-based Biosensor Development
- GlycoNano™ Bioink Production for 3D Printing
- Glyconanoparticle Development Service
- Glyco™ Synthesis Platform